Daunorubicin API Manufacturers & Suppliers

Looking for Daunorubicin API 20830-81-3?

Description:

Here you will find a list of producers, manufacturers and distributors of Daunorubicin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Daunorubicin 

Synonyms:

Acetyladriamycin , Daunomycin , Daunorubicin , Daunorubicina , Daunorubicine , Daunorubicinum , Leukaemomycin C , Rubidomycin , Daunorubicin Hydrochloride  

Cas Number:

20830-81-3 

DrugBank number:

DB00694 

Unique Ingredient Identifier:

ZS7284E0ZP

Daunorubicin is a type of Anthracycline Derivatives

Anthracycline derivatives are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs). These compounds are structurally derived from anthracyclines, which are natural antibiotics produced by certain strains of Streptomyces bacteria. Anthracycline derivatives exhibit potent anticancer properties and are commonly used in the treatment of various types of cancer, including breast cancer, leukemia, and lymphomas.

These APIs exert their therapeutic effects by interfering with the DNA replication process in cancer cells. They inhibit the activity of topoisomerase enzymes, which are responsible for unwinding and rewinding DNA strands during replication. By disrupting this process, anthracycline derivatives prevent cancer cells from dividing and multiplying, ultimately leading to their death.

Doxorubicin and daunorubicin are two well-known examples of anthracycline derivatives. These drugs have demonstrated remarkable efficacy in the treatment of cancer and are considered key components of chemotherapy regimens. However, their clinical use is limited by potential side effects, including cardiotoxicity and myelosuppression.

Despite these challenges, anthracycline derivatives continue to play a crucial role in oncology due to their proven efficacy against various types of cancer. Ongoing research aims to develop modified derivatives with reduced toxicity and enhanced therapeutic benefits. By harnessing the potential of these APIs, researchers and pharmaceutical companies strive to improve cancer treatment outcomes and enhance patient well-being.

Daunorubicin (Anthracycline Derivatives), classified under Anticancer drugs

Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.

Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.

These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.

Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.

• LGM Pharma from United States, product country of origin World
• Meiji Seika from Japan, product country of origin Japan
• TAPI from Israel, product country of origin Israel
• Microbiopharm Japan from Japan, product country of origin Japan
• DZD Heze Pharma from China, product country of origin China
• Sterling Biotech from India, product country of origin India
• Zhejiang Hisun Pharma from China, product country of origin China
• Sicor from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.